Btk inhibitor combinations and dosing regimen

A combination dosing regimen for the treatment of a hematologic malignancy in a subject in need thereof comprising a first phase and a second phase, wherein the first phase is an administration of ibrutinib as a single-agent treatment for a first extended period of time, and the second phase is an administration of a combination of ibrutinib and an anti-CD20 therapeutic agent for a second extended period of time.

A combination dosing regimen for the treatment of chronic lymphocytic leukemia in a subject in need thereof comprising a first phase and a second phase, wherein the first phase is an administration of a BTK inhibitor as a single-agent treatment for a first extended period of time, and the second phase is an administration of a combination of the BTK inhibitor and an anti-CD20 therapeutic agent for a second extended period of time.

A combination dosing regimen for the treatment of chronic lymphocytic leukemia in a subject in need thereof comprising a first phase and a second phase, wherein the first phase is an administration of ibrutinib as a single-agent treatment for a first extended period of time, and the second phase is an administration of a combination of ibrutinib and an anti-CD20 therapeutic agent for a second extended period of time.

A method of treating a hematologic malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising a BTK inhibitor and an anti-CD20 therapeutic agent following a combination dosing regimen wherein the combination dosing regimen comprises administering the BTK inhibitor as a single-agent over a first extended period of time as a first phase prior to administering the combination of the BTK inhibitor and the anti-CD20 therapeutic agent over a second extended period of time as a second phase.

A method of treating a hematologic malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising ibrutinib and an anti-CD20 therapeutic agent following a combination dosing regimen wherein the combination dosing regimen comprises administering ibrutinib as a single-agent over a first extended period of time as a first phase prior to administering the combination of ibrutinib and the anti-CD20 therapeutic agent over a second extended period of time as a second phase.

A method of treating chronic lymphocytic leukemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising a BTK inhibitor and an anti-CD20 therapeutic agent following a combination dosing regimen wherein the combination dosing regimen comprises administering the BTK inhibitor as a single-agent over a first extended period of time as a first phase prior to administering the combination of the BTK inhibitor and the anti-CD20 therapeutic agent over a second extended period of time as a second phase.

A method of treating chronic lymphocytic leukemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising ibrutinib and an anti-CD20 therapeutic agent following a combination dosing regimen wherein the combination dosing regimen comprises administering ibrutinib as a single-agent over a first extended period of time as a first phase prior to administering the combination of ibrutinib and the anti-CD20 therapeutic agent over a second extended period of time as a second phase.

Use of a combination of a BTK inhibitor and an anti-CD20 therapeutic agent for treating a hematological malignancy in an individual in need thereof, wherein the combination comprising the BTK inhibitor and the anti-CD20 therapeutic agent is administered following a combination dosing regimen wherein the combination dosing regimen comprises administering the BTK inhibitor as a single-agent over a first extended period of time as a first phase prior to administering the combination of the BTK inhibitor and the anti-CD20 therapeutic agent over a second extended period of time as a second phase.